Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00929539 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients
A Phase 2 study of Type II Diabetes Mellitus, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 496
- Enrollment target
- 20
- Study locations
NCT00929539: Completed Phase 2 study of Type II Diabetes Mellitus, sponsored by Akros Pharma.
NCT00929539 is a Phase 2 study of Type II Diabetes Mellitus that has completed, run by Akros Pharma. The registered enrollment target is 496 participants, above the 103-participant average among 7 other Type II Diabetes Mellitus trials with a reported enrollment target (382% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00929539, a Phase 2 study of Type II Diabetes Mellitus, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 496 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of JTT-130 on diabetes as well as the safety and tolerability of JTT-130 in obese Type 2 diabetic patients.
Conditions Studied
Interventions
- DRUG JTT-130
- DRUG JTT-130 Placebo
Study Locations (20)
California
- - Encino
- - Los Angeles
- - Sacramento
- - Spring Valley
- - Valley Village
- - Walnut Creek
Florida
- - Delray Beach
- - Hialeah
- - Miami
- - New Port Richey
- - Ocala
Alabama
- - Birmingham
- - Muscle Shoals
- - Scottsboro
Arizona
- - Tucson
Connecticut
- - Waterbury
Georgia
- - Sandy Springs
Illinois
- - Chicago
Indiana
- - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
What the finished NCT00929539 record still lists
NCT00929539 is an interventional study that assigns participants to a tested intervention. The registered 496 participants enrollment target is mid-sized for trials with a published cap, above the 103-participant average among 7 other Type II Diabetes Mellitus trials with a reported enrollment target (382% higher).
The record links to 1 condition, with Type II Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which JTT-130 is the first listed.
NCT00929539 names 20 study sites across 9 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00929539 about?
NCT00929539 is a clinical study titled "Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients". The purpose of this study is to evaluate the effect of JTT-130 on diabetes as well as the safety and tolerability of JTT-130 in obese Type 2 diabetic patients.
What is the current status of trial NCT00929539?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 496 participants. The study started on 2009-06. Estimated completion is 2010-07.
What conditions does trial NCT00929539 study?
This clinical trial studies the following conditions: Type II Diabetes Mellitus.
What interventions are being tested in trial NCT00929539?
The interventions under investigation include: JTT-130 (DRUG), JTT-130 Placebo (DRUG).
Who is sponsoring clinical trial NCT00929539?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00929539 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type II Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
RECRUITING · Phase 2
-
The GRoceries Aimed at Increasing Nutrition Study
RECRUITING · NA
-
Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
RECRUITING · Phase 1
-
Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes
COMPLETED · NA
-
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
COMPLETED · Phase 3
-
The Use of a Computer Program to Help Primary Care Providers Treat Patients With Type 2 Diabetes
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- NCT06778447 · 496 participants · NA
Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia